乳腺癌组织内转录因子E2F-4与雌激素受体/人表皮生长因子受体-2表达、临床分期及预后的关系

The relationship between the expression of E2F-4 and ER/HER-2 in human breast cancer and its association with clinical stage and prognosis

目的:观察乳腺癌组织内转录因子E2F-4的表达水平与雌激素受体(ER)/人表皮生长因子受体-2(HER-2)表达、临床分级、分期及预后的关系。方法:应用免疫组织化学技术,检测53例乳腺癌组织中E2F-4、ER、HER-2的表达,以正常乳腺组织作为对照,分析E2F-4的表达水平与ER、HER-2的表达及临床分级、分期、预后间的关系。结果:免疫组化结果显示14例正常乳腺组织内2例(14.3%)E2F-4低表达,其余组织内则呈阴性;53例乳腺癌组织内41例(77.4%)高表达E2F-4;E2F-4高表达与临床分期有关(P<0.05);与ER、HER-2表达无明显的相关性,与术后1年生存率无显著相关(P>0.05)。结论:E2F-4高水平表达可作为乳腺癌不良预后的重要的指标。

Objective：To investigate the relationship between the expression of E2F-4 and ER/HER-2 in human breast cancer and its association with clinical stage and prognosis. Methods： Immunohistology was used to analysies the expression level of E2F-4, ER and HER-2 expression in 53 breast cancer tissues, and their expression in normal tissue was used as the control. The relationship was analysed between E2F-4 and ER/HER-2 in human breast cancer and elinieal stage and prognosis. Results： The E2F-4 expression was higher in 2 of the 14 normal breast tissues 14.3% and in 41 of the 53 breast cancer tissues 77.4%. It was not related with the expression of ER and HER-2 or the survival rates. Conclusion：The high level of E2F-4 could be used as an important index to detect the bad prognosis.